Biofarm Bucure Asset Resilience Ratio
Biofarm Bucure asset resilience ratio. Biofarm Bucure (BIO) has an Asset Resilience Ratio of 8.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biofarm Bucure liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biofarm Bucure (2020–2025)
Asset resilience ratio of Biofarm Bucure from 2020 to 2025. This chart shows how Biofarm Bucure's Asset Resilience Ratio has changed over time. Read Biofarm Bucure (BIO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biofarm Bucure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 0% |
| Short-term Investments | RON55.00 Million | 8.67% |
| Total Liquid Assets | RON55.00 Million | 8.67% |
Asset Resilience Insights
- Limited Liquidity: Biofarm Bucure maintains only 8.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biofarm Bucure Industry Peers by Asset Resilience Ratio
Compare Biofarm Bucure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Biofarm Bucure Asset Resilience Ratio by Year (2020–2025)
Biofarm Bucure asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Biofarm Bucure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 8.67% | RON55.00 Million ≈ $12.63 Million |
RON634.39 Million ≈ $145.67 Million |
-2.49pp |
| 2024-09-30 | 11.16% | RON62.00 Million ≈ $14.24 Million |
RON555.48 Million ≈ $127.55 Million |
-7.27pp |
| 2023-09-30 | 18.43% | RON91.00 Million ≈ $20.90 Million |
RON493.81 Million ≈ $113.39 Million |
+12.79pp |
| 2020-09-30 | 5.64% | RON21.00 Million ≈ $4.82 Million |
RON372.38 Million ≈ $85.50 Million |
-- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more